BioMarin Exits Oncology Sector by Selling Talazoparib to Medivation in US$570 M Deal
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2015 Issue 10 (Table of Contents)
Published: 8 Oct-2015
DOI: 10.3833/pdr.v2015.i10.2125 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a front-loaded deal worth up to US$570 M, Medivation has move to expand its oncology franchise with the acquisition of BioMarin Pharmaceutical’s talazoparib (BMN 673), an oral poly(ADP ribose) polymerase (PARP) inhibitor being evaluated in a Phase III clinical trial for the treatment of BRCA-mutated breast cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS